Central nervous system (CNS) disorders are a therapeutic area in drug discovery where
demand for new treatments greatly exceeds approved treatment options. This is complicated …

The study of nicotinic acetylcholine receptors (nAChRs) has significantly progressed in the
last decade, due to a) the improved techniques available for structural studies; b) the …

Computational approaches represent valuable and essential tools in each step of the drug
discovery and development trajectory. Several computational methodologies are suitable to …

Despite Parkinson's Disease (PD) being the second most common neurodegenerative
disease, treatment options are limited. Consequently, there is an urgent need to identify and …

Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a
significant amount of time and resources with largely negative results. Repurposing drugs …

This paper reviews the effects of gut microbiota in regulating neurodegenerative diseases
through controlling gut-brain axis. Specific microbial populations and their metabolites (short …

A rigidification strategy was applied to the preclinical candidate donecopride, an
acetylcholinesterase inhibitor possessing 5-HT4R agonist activity. Inspired by promising …

In this review, we present the latest advances in the field of multi-target-directed ligand
(MTDL) design for the treatment of various complex pathologies of multifactorial origin. In …

Ion channels play a crucial role in a variety of physiological and pathological processes,
making them attractive targets for drug development in diseases such as diabetes, epilepsy …

Alzheimer's disease (AD) is a neurodegenerative disorder associated with cholinergic
dysfunction, provoking memory loss and cognitive dysfunction in elderly patients. The …